"About 100 candidate malaria vaccines have been developed over the past 30 years but only one has made it to the final, phase-three stage of clinical trials. However, this vaccine, known as "RTS,S" and made by GlaxoSmithKline, confers less than 50 per cent protection – which many experts believe is better than none."

"The new PfSEA-1 vaccine works by trapping malaria parasites inside infected red blood cells so that they cannot emerge to infect other red blood cells and so complete their complicated life cycle, said Jonathan Kurtis at Rhode Island Hospital in the US."


Good news, but more must come, targeting different mechanisms with multiple vaccines, etc., they say.
It is almost on the horizon.